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on behalf of the Dutch Chronic Subdural Hematoma Research Group (DSHR)-BACKGROUND: Chronic subdural hematoma (CSDH) is one of the more
frequent pathologic entities in daily neurosurgical practice. Historically, CSDH
was considered progressive recurrent bleeding with a traumatic cause. How-
ever, recent evidence has suggested a complex intertwined pathway of
inflammation, angiogenesis, local coagulopathy, recurrent microbleeds, and
exudates. The aim of the present review is to collect existing data on patho-
physiology of CSDH to direct further research questions aiming to optimize
treatment for the individual patient.
-METHODS: We performed a thorough literature search in PubMed, Ovid,
EMBASE, CINAHL, and Google scholar, focusing on any aspect of the patho-
physiology and nonsurgical treatment of CSDH.
-RESULTS: After a (minor) traumatic event, the dural border cell layer tears,
which leads to the extravasation of cerebrospinal fluid and blood in the subdural
space. A cascade of inflammation, impaired coagulation, fibrinolysis, and
angiogenesis is set in motion. The most commonly used treatment is surgical
drainage. However, because of the pathophysiologic mechanisms, the mortality
and high morbidity associated with surgical drainage, drug therapy (dexa-
methasone, atorvastatin, tranexamic acid, or angiotensin-converting enzyme
inhibitors) might be a beneficial alternative in many patients with CSDH.
-CONCLUSIONS: Based on pathophysiologic mechanisms, animal experi-
ments, and small patient studies, medical treatment may play a role in the
treatment of CSDH. There is a lack of level I evidence in the nonsurgical
treatment of CSDH. Therefore, randomized controlled trials, currently lacking,
are needed to assess which treatment is most effective in each individual
patient.
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As one of the more frequent pathologic
entities in daily neurosurgical practice,
chronic subdural hematoma (CSDH) is a
major topic in neurosurgical literature.
Moreover, CSDH is a public health issue
with an estimated 1-year incidence of
5e58/100,000, the highest in elderly
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).WORLD NEUROSURGERY-:-- , MONTH 2patients.1-7 Because it is expected that the
proportion of elderly citizens will double
in 2030, the CSDH incidence will likely
increase.8
The ﬁrst authentic description of a
clinical case that seems to describe CSDH,
came from Johannes Wepfer in 1657. He
described a “bloody cyst,” which he
discovered post mortem in the subdural
space of an elderly man. The man, just
before he died, had an apoplectic stroke
with aphasia and hemiplegia.9
The ﬁrst description of a craniectomy
for a CSDH was published almost a cen-
tury later by James Hill in 1751. He
described the injury and treatment of a girl018who fell off a horse. For the ﬁrst few days,
she had no complaints except amnesia,
but in the weeks to follow, she experi-
enced progressive headaches, nausea, and
vomiting. After 5 weeks, a trepanation was
performed in which ‘black liquid blood’
appeared from under the dura. She
recovered immediately after surgery.10
Houssard was the ﬁrst to describe the
CSDH as a clot surrounded by developing
membranes in 1817. Bayle also described
these membranes in 1826. He stated that
the lamination could be caused by recurrent
hemorrhages.11 In 1857, Virchow
formulated CSDH as “pachymeningitis
hemorrhagica chronica interna” andwww.WORLDNEUROSURGERY.org 1
Figure 1. Literature search. CSDH, chronic subdural hematoma. *See Appendix for the search strategies.
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trauma, but the lesion itself was more
likely to be caused by chronic
inﬂammation of the dura. He described
the histology and formation of (neo)
membranes: a process of “chronic
inﬂammation” in the dura followed by
ﬁbrin formation and proliferation of
capillaries from the dura with
extravasation of blood into the subdural
space.12,13 This theory of inﬂammation of
the dura became widely accepted until in
1914 Trotter proposed a traumatic cause of
this lesion.14 Throughout the twentieth
century, many different theories came up
for the latent interval between trauma and
the onset of symptoms in patients with
CSDH. The CSDH was proposed as being
a chronic or recurrent bleeding,15 possibly
expanded through osmotic pressure16 or
increased as a result of recurrent
microhemorrhage after an initial small
CSDH.17,18 The idea was adopted that
CSDH is a progressive bleeding that can
develop after (mild) trauma,
spontaneously, out of an acute subdural
hematoma or after a subdural
hygroma.19-23 However, it has been
recently suggested that a more complex
intertwined pathway of angiogenesis,
inﬂammation, recurrent microbleeds,
exudates, and local coagulopathy is
involved.24,25
The management of CSDH may consist
of surgery (burr-hole craniostomy [BHC]),
a temporary high dose of corticosteroids
as monotherapy or as an adjunct to sur-
gery, or watchful waiting. There is no2 www.SCIENCEDIRECT.comconsensus on optimal CSDH treatment,
because none of the available treatment
modalities has been evaluated in compar-
ative randomized clinical trials. The fact
that its pathophysiologic mechanism has
not been fully elucidated further compli-
cates the matter. Consequently, as more
research is directed toward this area, the
hydra paradox comes into effect: best
practice for treatment has not been
established and evolving research data
raises an increasing number of unsolved
questions. Despite the increased research
and advances in surgery and technology,
little has changed in the management of
patients with CSDH in the last decades.
The treatment of CSDH is associated with
serious morbidity, mortality, and recur-
rence rates.1,5,26-33
This review aims to collect existing data
on pathophysiology of CSDH to direct
further research questions aiming to opti-
mize treatment for the individual patient.METHODS
A broad Medline (PubMed and Ovid),
EMBASE, CINAHL, and Google scholar
search (for gray literature) was performed
to review the pathophysiology of CSDH
(see Appendix for the search strategies).
This search yielded 3970 results, 1866
after removal of double references. The
results were evaluated using the PRISMA
(Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) statement.34
Fifty-eight papers were included in the
review (Figure 1).WORLD NEUROSURGERY, httpOriginal articles and basic, trans-
lational, and clinical studies including >10
patients focusing on any aspect of the
pathophysiology of CSDH (molecular
markers, cytokines, inﬂammation, or
coagulation) were included. Reviews, case
reports, and pediatric series were
excluded.
Risk of bias assessment was performed
by the ﬁrst 2 authors (V.V. and D.H.) us-
ing, among others, the QUADAS-2 tool.35
For biomarkers, we used no speciﬁc tool.
The uncertainties were discussed with
the senior author (R.D.) and the conﬂicts
were resolved. However, because of the
scarcity of evidence and research in this
area, no articles were excluded on these
grounds. All articles had a relatively high
risk of bias given the generally small
sample sizes and lack of external
validation of results.Topics of Interest
To discuss all relevant aspects concerning
the pathophysiology and treatment of the
CSDH, we focus on the following subjects:
1) Anatomic consideration and membranes
2) Inﬂammatory pathways
3) Angiogenesis and growth factors
4) Coagulopathy and hyperﬁbrinolysis
and exudation
5) Proteome and hormones
6) Nonsurgical treatment of CSDH.s://doi.org/10.1016/j.wneu.2018.05.037
Figure 2. The pathophysiology of chronic subdural hematoma; this cycle perpetuates. CSF,
cerebrospinal fluid; VEGF, vascular endothelial growth factor.
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Anatomic Consideration and Membranes
The Subdural Space. The subdural space
was described in several human and
anatomic studies and in a review by
Haines et al.36,37 CSDH was initially
regarded as a thin lamina of ﬂuid between
the dura mater and the arachnoid mater, a
well-accepted theory accepted even in the
twentieth century.38 However, the
so-called subdural space is a layer of
cells called dural border cells, which have
junctions that are less tight than the rest of
the properly bound dura and arachnoid
mater.37 In 1936, Munro had already
shown in his surgical pathology series
that within 24 hours after the event
responsible for the initiation of CSDH,
ﬁbroblasts lining the underside of the
dura, in the vicinity of dural border cells,
begin to form an outer membrane that is
for the most part fully developed within 1
week.39 Within 3 weeks, the inner
membrane, much thinner, is also fully
constituted. These ﬁndings were later
conﬁrmed through electron microscopy.40
The trigger for the chain of events
leading to a CSDH with mass effect is
likely to be a minor traumatic event that
causes tearing of the dural border cell layer
and the extravasation of cerebrospinal
ﬂuid (CSF) and blood in the now existing
subdural space. The mass effect appears
because of extravasation of CSF in the
subdural space and not as a result of theWORLD NEUROSURGERY-:-- , MONTH 2hematoma itself.41 The CSF sets a cascade
of inﬂammation, impaired coagulation,
ﬁbrinolysis, and angiogenesis (Figure 2).
Before discussing these parameters in
more detail, we focus on the role of the
membranes.
The Membranes. The external membrane
has abundant blood vessels, with giant
capillaries having a large lumen similar to
veins, but without pericyte investment or
smooth muscle cells. These capillaries
show abnormal permeability through the
large gaps and sparse basal membrane
permitting the direct spill of vascular
contents in the extravascular space.42
There are also wide gaps, 0.4e1 mm,
between adjacent endothelial cells,
facilitating the transport of substances
and migration of cells as they would
from intercellular gaps of venules in
inﬂamed tissue. During the course of
disease, vesicles are seen within
capillaries pointing toward the evacuation
of hematoma contents.17 Furthermore,
the membrane contains active
ﬁbroblasts, a large number of collagen
ﬁbrils, and migrating cells (Figure 3,
Table 1).
The inner membrane contains 4 sepa-
rate layers, from external to internal: the
hematoma surface; the intermediate layer,
in which sometimes eosinophils and
edematous ﬂuid are found in the dilated
extracellular space; the arachnoid surface
layer with blood pigments, ﬁbrins, and018ﬁbrinoid substance among loosely tied
collagen ﬁbrils and elastin; and the ﬁnal
layer, in which the cells scarcely show the
tight intercellular junctions such as des-
mosomes that are to be expected from the
arachnoid mater.43
Inflammatory Pathways
With progression of disease, fewer cellular
and vascular structures and more ﬁbrous
tissue are present in the membranes.
Fibroblasts are recruited by basic ﬁbro-
blast growth factor and the release of
chemokines. The ﬁbroblasts organize on
the dural side of the outer membrane.
Some of these ﬁbroblasts become myoﬁ-
broblasts, which in electron microscopy
studies resemble smooth muscle cells.
Their presence might be attributable to a
physiologic reaction also seen in athero-
matous plaques or granulation tissue.44
Myoﬁbroblasts produce chemokines to
recruit inﬂammatory cells to the
inﬂammation epicenter.45 The dural
border cells organize the inner
membrane with help from the arachnoid
mater, which becomes adherent to it.
Inﬂammation in CSDH is a local pro-
cess, as shown by normothermia and
absence of increased/augmented systemic
inﬂammatory markers such as C-reactive
protein and erythrocyte sedimentation
rate. Cytokines, such as the proin-
ﬂammatory tumor necrosis factor a,
interleukin 6 (IL-6), chemokine IL-8, and
the antiinﬂammatory IL-10, are present at
higher concentrations in CSDH ﬂuid than
in serum.46 Because CSDH is an
encapsulated collection, it is unlikely that
CSF may permeate the subdural cavity
once CSDH is formed.46 Therefore, the
likely source of cytokines is represented
by ﬁbroblasts, endothelial cells, and
inﬂammatory cells found in the
membrane, because these types of cells
are known to secrete inﬂammatory
markers in response to bleeding.47
IL-6 can cause enlargement of endo-
thelial gap junctions with subsequent
increased vascular permeability,48
probably via the JAK/STAT3 (Janus
kinase-signal transducer and activator of
transcription) pathway,49 a phenomenon
that is also described in the membrane
of the CSDH. IL-8 promotes leukocyte
recruitment to sites of inﬂammation or
injury by activating integrins and subse-
quently by promoting migration throughwww.WORLDNEUROSURGERY.org 3
Figure 3. Histologic study of the outer membrane of chronic subdural
hematoma. Notice the erythrocytes are inferior and the proliferating
fibroblasts are superior. This histologic specimen is dated 7 days after the
episode of bleeding. Source: permission received from Jan Leestma, forensic
neuropathologist.
LITERATURE REVIEW
DANA C. HOLL ET AL. PATHOPHYSIOLOGY AND TREATMENT OF CSDHthe extracellular matrix.50,51 It is a potent
angiogenic factor, which may partly
explain why it is signiﬁcantly increased in
the layering type of hematoma.46
On magnetic resonance imaging (MRI),
T1 hyperintense CSDH showed higher
concentrations of IL-6 and IL-8, whereas
T2 hyperintense hematomas showed
higher concentrations of b-trace protein in
the subdural ﬂuid compared with the
serum. These ﬁndings seem to be associ-
ated with recurrences in hyperintense T1
hematomas and CSF admixture in hyper-
intense T2 hematomas, respectively.52
Levels of IL-10 seem also to be
increased in CSDH hematoma ﬂuid, even
although it is an antiinﬂammatory cyto-
kine. The patients with increased levels of
IL-10 also have higher levels of IL-6 and
IL-8,53 but layering hematomas were
correlated with a lower IL-10 level in the
ﬂuid.54 A high level of IL-6 and IL-8 with a
high level of IL-10 is indicative of
nonspeciﬁc inﬂammation and may sug-
gest that the process can be self-limiting.53
The membranes show prominent inﬁl-
tration of degranulated eosinophils and
lymphocytes, whereas within the hema-
toma, eosinophil counts are only slightly
increased.55 Lymphocytes release
chemoattractants, drawing the
eosinophils to the site of injury.56 Most4 www.SCIENCEDIRECT.comlikely, eosinophils promote
hyperﬁbrinolysis by the release of
plasminogen, ﬁbrosis in the ﬁbroblasts
of the outer membrane, and
phagocytosis of metabolites, and even
resorption of hematoma products.57-59
Another inﬂammatory pathway is the
cyclooxygenase 2 (COX-2)eprostaglandin
E2 (PGE2) pathway.
60 COX-2 triggers the
synthesis of PGE2, which in turn stimulates
the overexpression of vascular endothelial
growth factor (VEGF), responsible for
induction of angiogenesis. COX-2 is over-
expressed in the outer membrane, espe-
cially in endothelial cells and in
inﬂammatory cells. Among these cells are
numerous CD-68-positive macrophages,
whichmay cause the increased level of PGE2
in the subdural ﬂuid compared with serum.
Angiogenesis and Growth Factors
VEGF is one of the key angiogenic factors,
originally described as a tumor-secreted
protein named the vascular permeability
factor, which causes substantial vascular
leakage.61 VEGF and the proangiogenic
factor angiopoietin 2, create an unstable
condition with the continuous formation
of new and immature capillaries causing
extravasation and recurrent microbleeds.62
Also, hypoxia-inducible factor 1a plays
an important role in the process of vesselWORLD NEUROSURGERY, httpformation. It is induced by hypoxia and
strongly present in the outer membrane
and correlates strongly with VEGF pres-
ence.63 Levels of VEGF and basic ﬁbroblast
growth factor are higher in subdural ﬂuid
than in serum and show a strong presence
in the neomembrane as well.61,64
VEGF is produced by macrophages,
plasma cells in the membranes, and
endothelial cells of the fragile micro-
capillaries of the outer membrane. It is
suggested that one of the therapeutic as-
pects of surgical drainage of the hema-
toma and washing of the subdural space
disrupts the cycle of autocrine cell stimu-
lation of VEGF by strongly decreasing its
level in the hematoma cavity.65
Besides VEGF, which regulates endo-
thelial cell survival through the phospha-
tidylinositol 3-kinase/Akt/endothelial
nitric oxide synthase pathway,66 2 other
pathways contribute to the CSDH
pathogenesis. The Ras/mitogen-activated
protein kinase/extracellular signal-
regulated kinase pathway, activated by
IL-6 and VEGF, has a role in endothelial
cell proliferation and migration and the
transforming growth factor b/activin
receptorlike kinase 1 pathway, which is
essential for the formation and remodel-
ing of new vessels. These pathways all
represent intracellular ways in which
VEGF exerts its effects. Further research
into the upregulation and downregulation
of these pathways, as well as into the
factors that inﬂuence them, is required to
draw the line between normal endogenous
repair processes and pathologic VEGF
activation and possible halting of its
effects.
The exudation rate of VEGF and albu-
min in the subdural ﬂuid can be related to
computed tomography (CT) appearance,
using the Nomura classiﬁcation.67
Nomura made a subdivision into 5 types
of CSDH according to their appearance
on CT: high density, isodensity, low
density, mixed density, and layering. The
mean VEGF concentration was highest in
mixed density hematomas.68,69 There is
also a signiﬁcant correlation between the
VEGF concentration and MRI
appearance.70-72
Coagulopathy, Hyperfibrinolysis, and
Exudation
Next to inﬂammation and angiogenesis,
coagulopathy, hyperﬁbrinolysis, ands://doi.org/10.1016/j.wneu.2018.05.037
Table 1. Factors Involved in the Pathophysiology of Chronic Subdural Hematoma
Inflammatory Pathway
Fibroblasts (Myo)fibroblasts produce chemokines
bFGF (basic fibroblast growth factor) Recruits fibroblasts
Lymphocytes Release chemoattractants drawing the eosinophils to the site of injury
Eosinophils Releases plasminogen, promotes fibrosis in the fibroblasts, phagocytosis of
metabolites, and resorption of hematoma products
IL-8 (interleukin) Inflammatory marker; promotes leukocyte recruitment to sites of inflammation
or injury
IL-6 (interleukin) Inflammatory marker; enlarges the endothelial gap junctions, which increases
the vascular permeability
IL-10 (interleukin) Antiinflammatory marker, lower IL-10 in layering hematomas. If IL-6, IL-8, and
IL-10 are high, this is indicative of a nonspecific inflammation and suggests a
self-limiting process
Janus kinase-signal transducer and activator of transcription pathway Effector pathway by which IL-6 exerts its pathogenic effects in CSDH
Cyclooxoygenase 2 (COX-2)eprostaglandin E2 (PGE2) pathway COX-2 triggers the synthesis of PGE2 from arachidonic acid, which in turn
stimulates the overexpression of VEGF
Angiogenesis and Growth Factors
HIF-1a (hypoxia-inducible factor 1a) Transcription factor that regulates VEGF, present in the outer membrane
PGE2 (prostaglandin E2) Stimulates the overexpression of VEGF
VEGF (vascular endothelial growth factor) Proangiogenic factor, increased in the subdural fluid and neomembrane
MMP-9 (matrix metalloproteinase 9) Reduced absorption of CSDH because of increased vascular permeability,
enhanced inflammation, and reduction of vascular maturation
MAPK pathways (mitogen-activated protein kinase) Regulates proliferation and migration of endothelial cells, possibly activated
by VEGF and IL-6
PI3/Akt/endothelial nitric oxide synthase pathway VEGF regulates endothelial cell survival through this pathway
Transforming growth factor b/activin receptorlike kinase 1(ALK-1) pathway Essential for the formation and remodeling of new vessels
Coagulopathy, Hyperfibrinolysis, and Exudation
Plasminogen The inactive precursor of plasmin
t-PA (tissue plasminogen activator) Activates plasminogen, which is converted to plasmin. Activated plasmin
degrades coagulation factors V, VIII, and XI
Thrombin Thrombin catalyzes the conversion of fibrinogen into fibrin
FDPs (fibrinogen degradation products) Includes fibrin monomer and D-dimers. D-dimers inhibit platelet aggregation
and fibrin polymerization
TM (thrombomoduline) Thrombin receptor on endothelial cells of the capillaries that inhibits blood
clotting by binding with thrombin and the activated protein C. It is expressed
and increases after vascular endothelial injury
Ang-2 (angiopoietin 2) Proangiogenic factor that, in combination with VEGF, leads to the formation of
immature capillaries
Proteome and Hormones
TGFbI (transforming growth factor-b-induced protein Ig-H3) Protein, responds to tissue injury and has a role in wound healing. In CSDH, it
plays an important role in the proliferation of the membrane and the
meningeal reaction to the subdural collection
PICP (propeptide of type I collagen) and PIIINP (aminoterminal propeptide of
type III procollagen)
Increased in the subdural fluid; indicating a long-lasting upregulation of
collagen synthesis
CSDH, chronic subdural hematoma; VEGF, vascular endothelial growth factor.
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the maintenance of the hematoma and
explain why there is continuous bleeding
in the cavity and no clot.
The inﬂammatory mediators stimulate
the vascular permeability and release tis-
sue plasminogen activator (t-PA) from
endothelial cells. The level of t-PA in the
hematoma ﬂuid was found to be signiﬁ-
cantly higher than in plasma.73 These
levels correlated with the size of the
hematoma and clinical status of the
patient: patients with stupor and coma
had signiﬁcantly higher levels of t-PA
than did patients with headache or
somnolence. The t-PA levels also related
to the aspect on the CT scan, on which
layering hematomas show higher levels.73
t-PA activates plasminogen, which is
then converted to plasmin. The activity
of plasmin in the subdural ﬂuid together
with normal plasmatic levels shows local
hyperﬁbrinolytic activity.74 Moreover,
hematoma ﬂuid contains a low amount
of plasminogen when compared with
serum, because of its ongoing conversion
to plasmin, and a higher amount of
ﬁbrinogen degradation products,
including ﬁbrin monomer and D-dimers.
D-dimers inhibit platelet aggregation and
ﬁbrin polymerization, whereas the
activated plasmin degrades coagulation
factors V, VIII, and XI.75 Thus, the
consequences are an impaired platelet
function, a defective ﬁbrin clot, and an
important hemostatic imbalance.76
Subdural ﬂuid collected 24 hours after
surgery showed reduced t-PA and
ﬁbrinogen degradation products levels,77
signifying the re-establishment of a bal-
ance between coagulation and ﬁbrinolysis.
Thrombin also plays an important role
in the progression of CSDH. The
thrombin-antithrombin III complex and
prothrombin fragments 1 and 2 are
nonsigniﬁcantly increased in subdural
hygroma and signiﬁcantly increased in
CSDH, whereas levels of D-dimers, indi-
cating ﬁbrinolytic activity, are only
increased in CSDH. Thrombomodulin is
expressed and increased after vascular
endothelial injury. It is a thrombin recep-
tor on endothelial cells of the capillaries
that inhibits blood clotting by binding
with thrombin and the activated protein
C.54 It showed higher levels in mixed
density hematomas and the highest level
in laminar types.78 The extrinsic clotting6 www.SCIENCEDIRECT.comsystem becomes defective in the
development of CSDH, and the switch
from subdural hygroma to CSDH occurs
when ﬁbrinolysis begins to manifest.
Proteome and Hormones
The Subdural Hematoma Proteome. A recent
study has characterized the subdural he-
matoma proteome,79 in which 1100
proteins were analyzed for differences
with serum levels. In total, levels of 11
proteins were increased, most being
regulators of coagulation and ﬁbrinolysis.
Among those proteins were ﬁbrinogen,
corresponding to the state of
hyperﬁbrinolysis and hemoglobin a and
b levels, suggesting ongoing erythrocyte
lysis. Another protein with increased
level is transforming growth factor be
induced (TGFbI) ig-h3,79 which is
associated with tissue injury and wound
healing, making it probably responsible
for the proliferation of the membrane
and the meningeal reaction to the
subdural collection.
Complement values were shifted (C3ca)
and decreased (C4c), suggesting a role for
complement in the inﬂammatory reaction
that characterizes CSDH, but its speciﬁc
role has yet to be explored.
Two reports stated that propeptide of
type I collagen and the aminoterminal
propeptide of type III procollagen were
78-fold to 156-fold higher than in serum
from the period of 10e85 days after injury,
indicating a long-lasting upregulation of
collagen synthesis.80 Moreover, this
increase is time dependent in the ﬁrst
2 weeks and remains high for more than
3 months, whereas in dermal wound
healing, these levels normally decline
3 weeks after injury.81,82 The dural
ﬁbrosis reaction stays active even longer
than the one observed in subarachnoid
hemorrhage, which subsides after a
month.
Hormones. An intriguing area of research
was proposed in 1977 by observing high
urinary estrogen levels in male patients
with CSDH, suggesting that this might
play a role in the pathogenesis of the
disease.83 In 1984 and later in 1992,
positive staining for estrogen and
progesterone receptors in the membrane
of hematomas was shown. Estrogens
might inﬂuence the vascularized
membranes directly, including stimulatingWORLD NEUROSURGERY, httpsynthesis of t-PA. This characteristic could
be more pronounced in men whose
vascular system is less adapted to high
values of estrogen.84,85 However, these
theories could not be reproduced in a
later study.86
Nonsurgical Treatment of CSDH
Dexamethasone. Steroids might be an op-
tion in the nonsurgical treatment of
CSDH. Dexamethasone is known to be
antiinﬂammatory and has antiangiogenic
effects. Moreover, it is able to inhibit the
formation of new blood vessels. Over the
past decades, dexamethasone has been
assessed in multiple studies as mono-
therapy or as an adjunct to BHC.87-93
Dexamethasone is a noninvasive treat-
ment and might signiﬁcantly reduce
mortality and lead to a better outcome.94
Also, in some patients, this treatment led
to shorter hospitalization, making it
more cost-effective compared with BHC.
The downside of dexamethasone use is
a higher complication rate such as dia-
betes, infections, and (temporary) mental
changes. The mortality in studies using
dexamethasone for treatment of CSDH
varies between 0.8% and 4%.94
Thotakura and Marabathina identiﬁed
several variables (female sex, limited
midline shift and hematoma thickness,
and lower CT attenuation values) that are
associated with a good outcome after
conservative treatment with dexametha-
sone.92 Zhang et al.95 conclude that in
patients with recurrent CSDH,
dexamethasone treatment might avoid
reoperation. Prospective studies on the
role of dexamethasone in the treatment
of CSDH are ongoing.96,97
Atorvastatin. Besides its role in decreasing
levels of low-density lipoprotein choles-
terol, atorvastatin has also been widely
investigated in the management of CSDH.
Some small studies showed atorvastatin to
be safe and effective in the treatment of
CSDH, leading to a lower rate of
BHC.98-101 In mice models, a low dose of
atorvastatin (3 mg/kg/day) was found to
have antiinﬂammatory and antiangiogenic
effects.102
A proangiogenic effect of atorvastatin in
rats was described by Li et al.103 and Wang
et al.104 A higher dose of atorvastatin (8
mg/kg/day) led to a signiﬁcantly increased
and persistently high level of VEGF ands://doi.org/10.1016/j.wneu.2018.05.037
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matrix metalloprotease 9.104
Tranexamic Acid. Tranexamic acid might
inhibit the ﬁbrinolytic and inﬂammatory
(kinin-kallikrein) systems. In 1 study,105 it
was used as a primary medical
treatment, resulting in successful
treatment in 18 of 21 patients. In the
study of Tanweer et al.,106 tranexamic
acid was administered postoperatively.
No increase of hematoma or recurrences
were noted. A multicenter randomized
controlled trial started in October 2015 in
Canada, planning to randomize 130
patients to receive either tranexamic acid
or placebo.107
Angiotensin-Converting Enzyme Inhibitors.
Angiotensin-converting enzyme (ACE) in-
hibitors decrease VEGF production,
possibly resulting in a reduction of new
and immature vascularization, a decreased
extravasation of ﬂuid into the subdural
space, and a reduction of recurrence of
CSDH.108 In a prospective randomized
controlled trial,109 the ACE inhibitor
perindopril was tested against placebo;
there was no statistically signiﬁcant
effect on recurrence rate. Neidert et al.110
performed a retrospective case-control
study in which they found higher hema-
toma volumes and a higher frequency of
recurrences in patients treated with ACE
inhibitors as an addition to surgery. These
investigators hypothesize that this situa-
tion could be caused by an increase in
bradykinin levels, causing increased
vascular permeability of the neo-
membranes in CSDH.
DISCUSSION
Our review shows that, throughout his-
tory, different theories on the pathophys-
iology and treatment of CSDH have been
put forward. Using all data from the
literature search, we propose a contem-
porary unifying theory. A minor trauma
precedes the formation of a CSDH.
Trauma causes cleavage of the dural
border cells, after which CSF or CSF with
blood or a very small quantity of blood is
interposed between the broken cell layer
and the rest of the dura. The injured dural
cells release cytokines, attracting inﬂam-
matory cells, which inﬁltrate, especially
neutrophils and eosinophils. Some of the
ﬁbroblasts become myoﬁbroblasts andWORLD NEUROSURGERY-:-- , MONTH 2synthesize chemokines, recruiting more
inﬂammatory cells. Prostaglandins and
chemokines induce the expression of
VEGF, which in turn recruits endothelial
cells in the outer membrane. The imma-
ture capillaries without the basal mem-
brane, subjected to high pressure because
of lack of drainage on the one side and
negative pressure in the newly-formed
subdural space on the other side, allow
extravasation of all the vascular contents
into the hematoma cavity. Progressively
more eosinophils are recruited and plas-
minogen and thrombin are also poured
inside the cavity. Fibrin clots are dis-
integrated, and platelets cannot aggregate.
This process produces ongoing cell injury
and causes a further increase of inﬂam-
matory cells and VEGF production. The
cycle perpetuates and the hygroma be-
comes a CSDH. The membrane is fully
constituted and it takes even more damage
from the constant pulsating rhythm of the
intracranial contents and from changes of
position of the head.111 The CSDH grows
until it reaches a size that impairs CBF
and metabolism in adjacent brain
structures, leading to symptoms such as
hemiparesis and/or mental changes.
There is no consensus on the best
treatment for the individual patient diag-
nosed with CSDH. Trephination is inter-
nationally considered as the classic
standard treatment in symptomatic CSDH.
Trephination occurs through BHC, twist-
drill craniostomy, or even crani-
otomy.112-116 It consists of removing the
hematoma by rinsing the subdural space,
frequently followed by placing a temporary
drain in the remaining cavity. However,
surgery is also associated with recurrence,
mortality, infection, bleeding, or sei-
zures.1,5,6,26-32 The operation-related mor-
tality varies between 1.5% and 6% and
CSDH recurs in 20%e26% of
cases.29,94,117-120 Because of the mortality,
morbidity, and recurrence rates after sur-
gery and also considering the pathophys-
iologic mechanism of CSDH, other more
conservative options in the treatment of
CSDH are worth investigating. The stim-
ulation of vessel maturation and antiin-
ﬂammatory pathways may contribute to
the resolution of CSDH and may induce
neurologic recovery.121
The literature suggests that drug ther-
apy might be useful as a monotherapy or
as an adjunct to surgery in patients018diagnosed with CSDH. Drugs that might
be effective are dexamethasone, atorvas-
tatin, tranexamic acid, and ACE in-
hibitors. Dexamethasone is believed to
intervene in the perpetuating pathophysi-
ologic cycle through its antiinﬂammatory
and antiangiogenic effects. However,
properly designed randomized controlled
trials need to be carried out to provide
high-quality data to enforce clinical deci-
sion making. The use of atorvastatin in the
treatment of CSDH is questionable,
because of the contradictory ﬁndings in
some studies performed. Tranexamic acid
might intervene in the ﬁbrinolytic and
inﬂammatory pathways, but evidence is
based on small retrospective studies. It is
hypothesized that ACE inhibitors decrease
the amount of VEGF and with that
decrease, the volume of the CSDH. How-
ever, clinical studies have not conﬁrmed
this theory. Moreover, a small retrospec-
tive study suggests that treatment with
ACE inhibitors might increase hematoma
volumes and recurrence rate.CONCLUSIONS
Based on pathophysiologic mechanisms,
animal experiments, and small patient
studies, medical treatment may play a role
in the treatment of CSDH. Medical treat-
ment could be administered as a mono-
therapy or as an adjunct to the classic
surgical treatment, consisting of hema-
toma drainage. Further research is needed
to assess which treatment is most beneﬁ-
cial in each individual patient diagnosed
with CSDH. For this purpose, adequately
sized multicenter prospective randomized
controlled trials on the treatment of CSDH
seem most valuable. Moreover, basic
research aimed at unravelling the patho-
physiology of CSDH is required.ACKNOWLEDGMENTS
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